PE20151769A1 - Variantes de pertuzumab y su evalaucion - Google Patents
Variantes de pertuzumab y su evalaucionInfo
- Publication number
- PE20151769A1 PE20151769A1 PE2015002163A PE2015002163A PE20151769A1 PE 20151769 A1 PE20151769 A1 PE 20151769A1 PE 2015002163 A PE2015002163 A PE 2015002163A PE 2015002163 A PE2015002163 A PE 2015002163A PE 20151769 A1 PE20151769 A1 PE 20151769A1
- Authority
- PE
- Peru
- Prior art keywords
- pertuzumab
- variants
- compositions
- evalaution
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Electrochemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A VARIANTES DE PERTUZUMAB, PARTICULARMENTE UNA VARIANTE DE CISTEINA NO APAREADA QUE COMPRENDEN LOS RESIDUOS Cys23/Cys88 SIN APAREAR EN UNO O AMBOS DOMINIOS VARIABLES LIVIANOS DE PERTUZUMAB; UNA VARIANTE AFUCOSILADA DE PERTUZUMAB; UNA ESPECIE DE BAJO PESO MOLECULAR (LMWS) DE PERTUZUMAB; Y UNA ESPECIE DE ALTO PESO MOLECULAR (HMWS) DE PERTUZUMAB. TAMBIEN SE REFIERE A VARIANTES AISLADAS DE PERTUZUMAB, COMPOSICIONES, COMPOSICIONES FARMACEUTICAS, Y ARTICULOS DE FABRICACION COMPRENDIENDO DICHAS VARIANTES, ASI COMO A METODOS DE PREPARACION Y CARACTERIZACION DE DICHAS VARIANTES Y COMPOSICIONES DE LAS MISMAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361812603P | 2013-04-16 | 2013-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151769A1 true PE20151769A1 (es) | 2015-12-11 |
Family
ID=50694078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000128A PE20211214A1 (es) | 2013-04-16 | 2014-04-15 | Variantes de pertuzumab y su evaluacion |
PE2015002163A PE20151769A1 (es) | 2013-04-16 | 2014-04-15 | Variantes de pertuzumab y su evalaucion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000128A PE20211214A1 (es) | 2013-04-16 | 2014-04-15 | Variantes de pertuzumab y su evaluacion |
Country Status (25)
Country | Link |
---|---|
US (7) | US9815904B2 (es) |
EP (2) | EP2986643A2 (es) |
JP (2) | JP2016522176A (es) |
KR (2) | KR20200085942A (es) |
CN (1) | CN105121471A (es) |
AR (1) | AR095863A1 (es) |
AU (3) | AU2014254086B2 (es) |
BR (1) | BR112015024926A2 (es) |
CA (2) | CA2907776C (es) |
CL (3) | CL2015003049A1 (es) |
CR (1) | CR20150576A (es) |
EA (1) | EA201591643A1 (es) |
HK (1) | HK1211948A1 (es) |
IL (2) | IL241103B (es) |
MA (1) | MA38567A1 (es) |
MX (2) | MX368259B (es) |
MY (1) | MY173295A (es) |
NZ (2) | NZ751877A (es) |
PE (2) | PE20211214A1 (es) |
PH (1) | PH12015502382A1 (es) |
RU (2) | RU2019115089A (es) |
SG (3) | SG10201706045RA (es) |
TW (1) | TWI554284B (es) |
WO (1) | WO2014172371A2 (es) |
ZA (1) | ZA201506594B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
JP5711751B2 (ja) | 2009-10-26 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | グリコシル化された免疫グロブリンの調製方法 |
KR20200085942A (ko) | 2013-04-16 | 2020-07-15 | 제넨테크, 인크. | 페르투주맙 변이체 및 그의 평가 |
JP6914336B2 (ja) * | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
HRP20240069T1 (hr) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvantno liječenje her2-pozitivnog raka dojke |
AU2018258263A1 (en) * | 2017-04-24 | 2019-10-24 | Genentech, Inc. | ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain |
US20200271663A1 (en) * | 2017-09-13 | 2020-08-27 | Mayo Foundation For Medical Education And Research | Identification and monitoring of acid hydrolysis products of immunoglobulin heavy chains |
JP7259778B2 (ja) | 2020-01-31 | 2023-04-18 | トヨタ自動車株式会社 | 車両、及び自動運転システム |
CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
TW202308701A (zh) | 2021-04-29 | 2023-03-01 | 大陸商上海匯連生物醫藥有限公司 | 抗體偶聯藥物的製備方法及應用 |
KR102511384B1 (ko) | 2022-04-14 | 2023-03-16 | 지용환 | 곡물의 손상을 줄일 수 있는 도정기 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3934085A (en) | 1984-01-30 | 1985-08-09 | Icrf Patents Ltd. | Improvements relating to growth factors |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
ATE155813T1 (de) | 1989-05-19 | 1997-08-15 | Genentech Inc | Her2 extrazellulare domäne |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
ES2335365T3 (es) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
IL138034A0 (en) | 1998-03-27 | 2001-10-31 | Genentech Inc | Apo-2 ligand-anti-her-2 antibody synergism |
CN103641885A (zh) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
AU782325B2 (en) | 1999-05-14 | 2005-07-21 | Genentech Inc. | Treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP4579471B2 (ja) | 1999-06-25 | 2010-11-10 | ジェネンテック, インコーポレイテッド | 抗ErbB2抗体を用いる前立腺癌の処置 |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
KR20090024308A (ko) | 1999-08-27 | 2009-03-06 | 제넨테크, 인크. | 항-ErbB2 항체 투여 치료 방법 |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
JP2003534292A (ja) | 2000-05-19 | 2003-11-18 | ジェネンテック・インコーポレーテッド | Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
IL156618A0 (en) | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
ES2376165T3 (es) * | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4. |
DK2332996T3 (en) | 2002-09-11 | 2014-12-15 | Genentech Inc | Purification of anti-Her2 antibodies |
JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
WO2005000898A2 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
EP3095793B1 (en) | 2003-07-28 | 2020-03-25 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | 疼痛治療のためのErbBアンタゴニスト |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
MX2007000723A (es) | 2004-07-22 | 2007-03-12 | Genentch Inc | Composicion de anticuerpos her2. |
CN101052654A (zh) | 2004-08-19 | 2007-10-10 | 健泰科生物技术公司 | 具有改变的效应子功能的多肽变体 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2005314127A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
AU2005315912A1 (en) | 2004-12-13 | 2006-06-22 | F. Hoffmann-La Roche Ag | Novel pharmaceutical composition containing at least one Dolastatin 10 derivative |
KR20130089280A (ko) | 2005-01-21 | 2013-08-09 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
MY152164A (en) | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
JP2009539836A (ja) | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長 |
US8015939B2 (en) | 2006-06-30 | 2011-09-13 | Asml Netherlands B.V. | Imprintable medium dispenser |
NZ574580A (en) | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
BRPI0808418A2 (pt) | 2007-03-02 | 2014-07-22 | Genentech Inc | Predição de resposta a um inibidor de her |
CA2681341A1 (en) * | 2007-03-22 | 2008-09-25 | Genentech, Inc. | Apoptotic anti-ige antibodies |
EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
JP5373776B2 (ja) | 2007-06-06 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | 腫瘍抗原に結合する無標識一次モノクローナル抗体と、nirフルオレセイン標識で標識された非交差反応性二次モノクローナル抗体から成る組成物 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
DK2171090T3 (da) | 2007-06-08 | 2013-06-10 | Genentech Inc | Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling |
LT3597659T (lt) | 2007-07-09 | 2023-05-10 | Genentech, Inc. | Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu |
ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
NZ584514A (en) * | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
SI2215117T2 (en) | 2007-10-30 | 2018-04-30 | Genentech, Inc. | Purification of the antibody by cation exchange chromatography |
CA2713342A1 (en) * | 2008-01-30 | 2009-08-13 | Abbott Laboratories | Compositions and methods for crystallizing antibody fragments |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
JP2011513432A (ja) | 2008-03-06 | 2011-04-28 | ジェネンテック, インコーポレイテッド | c−met及びHERアンタゴニストの併用療法 |
TWI527593B (zh) | 2008-03-18 | 2016-04-01 | 建南德克公司 | 抗her2抗體-藥物結合物及化療劑之組合及使用方法 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
FR2942799B1 (fr) * | 2009-03-06 | 2011-02-25 | Lfb Biotechnologies | Anticorps monoclonal anti-rhesus d |
EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AU2010335282B2 (en) * | 2009-12-22 | 2015-05-21 | Roche Glycart Ag | Anti-HER3 antibodies and uses thereof |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
MX2013006392A (es) | 2010-12-09 | 2013-12-06 | Genentech Inc | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
SG194472A1 (en) * | 2011-01-28 | 2013-12-30 | Ca Nat Research Council | Engineering of immunoglobulin domains |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
KR102679155B1 (ko) | 2011-10-14 | 2024-06-28 | 제넨테크, 인크. | Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품 |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
AU2013273489B9 (en) | 2012-06-08 | 2018-08-23 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-l1阻害剤併用療法を必要とする患者の同定 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
KR20200085942A (ko) | 2013-04-16 | 2020-07-15 | 제넨테크, 인크. | 페르투주맙 변이체 및 그의 평가 |
MX2016007887A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2. |
-
2014
- 2014-04-15 KR KR1020207019835A patent/KR20200085942A/ko not_active Application Discontinuation
- 2014-04-15 MA MA38567A patent/MA38567A1/fr unknown
- 2014-04-15 NZ NZ751877A patent/NZ751877A/en unknown
- 2014-04-15 CA CA2907776A patent/CA2907776C/en active Active
- 2014-04-15 JP JP2016509031A patent/JP2016522176A/ja not_active Withdrawn
- 2014-04-15 EP EP14723656.6A patent/EP2986643A2/en not_active Withdrawn
- 2014-04-15 RU RU2019115089A patent/RU2019115089A/ru unknown
- 2014-04-15 CA CA3071678A patent/CA3071678A1/en not_active Abandoned
- 2014-04-15 MY MYPI2015002532A patent/MY173295A/en unknown
- 2014-04-15 KR KR1020157032283A patent/KR20150143649A/ko active Application Filing
- 2014-04-15 WO PCT/US2014/034200 patent/WO2014172371A2/en active Application Filing
- 2014-04-15 AR ARP140101600A patent/AR095863A1/es unknown
- 2014-04-15 MX MX2015013898A patent/MX368259B/es active IP Right Grant
- 2014-04-15 EA EA201591643A patent/EA201591643A1/ru unknown
- 2014-04-15 RU RU2015141520A patent/RU2737727C2/ru active
- 2014-04-15 PE PE2021000128A patent/PE20211214A1/es unknown
- 2014-04-15 SG SG10201706045RA patent/SG10201706045RA/en unknown
- 2014-04-15 NZ NZ712012A patent/NZ712012A/en unknown
- 2014-04-15 CN CN201480020921.2A patent/CN105121471A/zh active Pending
- 2014-04-15 SG SG11201508536PA patent/SG11201508536PA/en unknown
- 2014-04-15 EP EP20201975.8A patent/EP3800204A1/en active Pending
- 2014-04-15 TW TW103113741A patent/TWI554284B/zh active
- 2014-04-15 PE PE2015002163A patent/PE20151769A1/es unknown
- 2014-04-15 SG SG10201911353WA patent/SG10201911353WA/en unknown
- 2014-04-15 US US14/253,038 patent/US9815904B2/en active Active
- 2014-04-15 BR BR112015024926A patent/BR112015024926A2/pt not_active Application Discontinuation
- 2014-04-15 AU AU2014254086A patent/AU2014254086B2/en active Active
-
2015
- 2015-09-03 IL IL241103A patent/IL241103B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06594A patent/ZA201506594B/en unknown
- 2015-10-01 MX MX2019005151A patent/MX2019005151A/es unknown
- 2015-10-14 PH PH12015502382A patent/PH12015502382A1/en unknown
- 2015-10-15 CL CL2015003049A patent/CL2015003049A1/es unknown
- 2015-10-15 CR CR20150576A patent/CR20150576A/es unknown
- 2015-12-24 HK HK15112673.2A patent/HK1211948A1/xx unknown
-
2017
- 2017-09-28 CL CL2017002445A patent/CL2017002445A1/es unknown
- 2017-10-19 US US15/788,598 patent/US20180037661A1/en not_active Abandoned
- 2017-10-19 US US15/788,574 patent/US9969811B2/en active Active
- 2017-10-19 US US15/788,632 patent/US20180037662A1/en not_active Abandoned
-
2018
- 2018-10-05 AU AU2018241141A patent/AU2018241141B2/en active Active
-
2019
- 2019-07-12 JP JP2019129841A patent/JP2020015719A/ja active Pending
- 2019-07-12 US US16/510,287 patent/US20190345258A1/en not_active Abandoned
- 2019-08-06 US US16/533,488 patent/US20200157238A1/en not_active Abandoned
- 2019-08-08 CL CL2019002244A patent/CL2019002244A1/es unknown
- 2019-10-22 AU AU2019253804A patent/AU2019253804A1/en not_active Abandoned
-
2020
- 2020-06-15 IL IL275398A patent/IL275398A/en unknown
-
2022
- 2022-06-27 US US17/809,098 patent/US20230047103A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151769A1 (es) | Variantes de pertuzumab y su evalaucion | |
CO2018006662A2 (es) | Agonistas del receptor de apelina y métodos de uso | |
NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
EA202090547A2 (ru) | Макроциклические деаза-оксипурины для лечения вирусных инфекций | |
SV2014004771A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
CR20160499A (es) | Composiciones estables de yodo no en complejo y métodos de uso | |
BR112016023851A2 (pt) | ?composição de revestimento de duas partes e método para revestir uma superfície? | |
EA201692269A1 (ru) | Новые композиции, их использование и способы получения | |
EA202091397A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
CO6571868A2 (es) | Procedimiento para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
DOP2016000014A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20150440A (es) | Nuevos derivados de piridina | |
EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20160448A (es) | Nuevos derivados de piridina | |
EA201690793A1 (ru) | Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c | |
CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
EA201600093A1 (ru) | Дигидроксифенильные нейромедиаторные соединения, композиции и способы | |
CL2012003402A1 (es) | Composición líquida natural antioxidante concentrada preparada sólo con componentes de hierbas y arbustos producidos bajo técnicas orgánicas, endulzada con stevia y el método de preparación de dicha composición. | |
NI201500172A (es) | Composiciones farmacéuticas | |
GT201200066A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
GT201700139A (es) | Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina |